Experimental drug talquetamab takes aim at stubborn myasthenia gravis
NCT ID NCT07499323
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This very early study will test the drug talquetamab in just 2 people with refractory generalized myasthenia gravis, a chronic autoimmune disease that causes muscle weakness. The drug is designed to help the immune system attack the cells that produce harmful antibodies. The goal is to see if it can improve daily living activities and reduce muscle weakness, while monitoring for side effects.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Talquetamab (a drug given as a shot under the skin)
What this could lead to
If it works, this could point toward a new treatment option for people with myasthenia gravis that doesn't respond to standard therapies.
What could go wrong
This is an extremely early study with only 2 participants, so results may not apply to others. The drug also has risks like immune reactions and side effects from targeting the immune system.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MYASTHENIA GRAVIS (MG) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.